Royal Bank Of Canada Processa Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.18 - $0.84 $13 - $63	-76 Reduced 0.16%	46,306 $15,000
Q3 2023 Nov 14, 2023	BUY	$0.24 - $0.53 $11,095 - $24,502	46,231 Added 30616.56%	46,382 $11,000
Q2 2023 Aug 14, 2023	BUY	$0.44 - $0.73 $66 - $110	151 New	151 $0
Q4 2022 Feb 14, 2023	SELL	$1.1 - $50.0 $16 - $750	-15 Reduced 1.48%	1,000 $1,000
Q3 2022 Nov 14, 2022	BUY	$2.0 - $46.8 $30 - $702	15 Added 1.5%	1,015 $2,000
Q4 2021 Feb 14, 2022	BUY	$4.03 - $8.42 $4,030 - $8,420	1,000 New	1,000 $5,000

Ticker PCSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,856,200
Market Cap $14.3M
Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosi...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.